Principal Scientist from Roche to speak on ADC development at the 5th ADC Summit in London.
With the FDA's recent approval of ADCs Adcetris and Kadcyla, the industry has reached a tipping point now that it has entered the commercial stage. New innovations in developing the next best generation ADCs are bursting into the clinic at a rapid rate.
Ben Fillippo Krippendorff, Principal Scientist at Roche, will be speaking at SMi's 5th ADC Summit in London taking place in London on 23-24 May 2016. Krippendorff will be speaking on Day 2 of the conference about predicting tissue distribution and clearance of antibody formats to improve selectivity of targeted therapies. His presentation will cover:
- Estimating the tissue distribution of antibodies and antibody fragments based on plasma pharmacokinetics
- Estimation of ADC distribution and tissue specific clearances that influence the therapeutic window
- Optimising biotherapeutic modalities with optimal biodistribution properties to targe (and avoid) specific tissues
The 5th ADC Summit will bring together leading industry professionals to explore the various innovations in approaches and technologies for the development of next generation ADCs. Event attendees will hear the latest insights from Takeda on Adcetris; discuss the latest advancements in research and development from Medimmune; and analyse case studies from big pharma companies such as Roche, Bayer, Pfizer, AstraZeneca, Novartis and many more.
For more information on speakers and their topics, visit the event website at www.adcsummit.com. An Early Bird discount of £200 applies to all online bookings made by 31 March.
For tailored sponsorship and branding opportunities contact Alia Malick on +44 (0) 20 7827 6168 or email: email@example.com. For group/delegate bookings contact Fateja Begum on +44 (0) 20 7827 6184 or email firstname.lastname@example.org.
For media enquiries contact Honey de Gracia on +44 (0) 20 7827 6102 or email email@example.com.